Related Experiment Videos

Neonatal familial hypercholesterolemia

Insights

Neonatal screening can identify infants with familial hypercholesterolemia, a genetic condition. Early diagnosis enables timely intervention to prevent premature heart disease in high-risk newborns.

Area of Science:

  • Pediatrics
  • Genetics
  • Cardiology

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder leading to high cholesterol levels.
  • Individuals with FH have a significantly increased risk of premature ischemic heart disease.
  • Early identification of FH is crucial for initiating preventative measures.

Purpose of the Study:

  • To evaluate the feasibility and outcomes of neonatal screening for familial hypercholesterolemia.
  • To assess cholesterol levels in neonates from hypercholesterolemic families.
  • To determine the potential for primary prevention of heart disease in this high-risk group.

Main Methods:

  • Studied hypercholesterolemic and normal neonates from affected families over 6 to 30 months.
  • Monitored plasma cholesterol levels at various ages (6, 12, 18 months).
  • Assessed the impact of low cholesterol intake on cholesterol levels in affected infants.

Main Results:

  • 16 of 22 hypercholesterolemic neonates and 8 of 11 normal neonates had FH.
  • Elevated cholesterol (>200 mg/100 ml) was observed in 8/16 hypercholesterolemic neonates by 6-12 months.
  • Dietary intervention normalized cholesterol in 5/7 affected infants by 6-12 months.

Conclusions:

  • Neonatal diagnosis of FH is possible and identifies infants at high genetic risk.
  • Early detection facilitates primary prevention strategies for ischemic heart disease.
  • Intervention, including dietary changes, can help manage cholesterol levels in affected infants.

Related Concept Videos